Lensar (LNSR) Net Income towards Common Stockholders (2019 - 2026)
Lensar's (LNSR) quarterly Net Income towards Common Stockholders came in at $18.9 million in Q1 2026, up 169.17% year-on-year from $7.0 million in Q1 2025, and up 1397.26% on a QoQ basis from -$1.5 million in Q4 2025.
Lensar (LNSR) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Lensar (LNSR) has 8 years of Net Income towards Common Stockholders data on file, last reported at $18.9 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 169.17% year-over-year to $18.9 million in Q1 2026; TTM through Mar 2026 was $12.0 million, a 121.17% increase from a year earlier, with the FY2025 full-year figure at -$34.3 million, down 9.16% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $18.9 million, up from -$1.5 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for LNSR reached as high as $18.9 million in Q1 2026 and fell as low as -$27.3 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged -$4.8 million across 5 years, with a median of -$3.9 million in 2023.
- Across the five-year window, Net Income towards Common Stockholders plunged 1167.73% in 2025 and soared 169.17% in 2026, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$2.5 million in 2022, then slumped by 57.67% to -$3.9 million in 2023, then slumped by 376.36% to -$18.7 million in 2024, then jumped by 92.2% to -$1.5 million in 2025, then soared by 1397.26% to $18.9 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $18.9 million in Q1 2026, -$1.5 million in Q4 2025, and -$3.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Lensar | 65.43 Mn | 54.33 Mn | 6.38 Mn | 18.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.91 Mn |
| Dec 31, 2025 | -1.46 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Jun 30, 2025 | -1.76 Mn |
| Mar 31, 2025 | -27.35 Mn |
| Dec 31, 2024 | -18.70 Mn |
| Sep 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -9.04 Mn |
| Mar 31, 2024 | -2.16 Mn |
| Dec 31, 2023 | -3.93 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | -8.75 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Dec 31, 2022 | -2.49 Mn |
| Sep 30, 2022 | -3.99 Mn |
| Jun 30, 2022 | -6.76 Mn |
| Mar 31, 2022 | -6.67 Mn |
| Dec 31, 2021 | -3.90 Mn |
| Sep 30, 2021 | -6.16 Mn |
| Jun 30, 2021 | -4.36 Mn |